Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
PREVENT was a randomised, double-blind phase 3 trial in which eculizumab was associated with a significantly lower risk of relapse than placebo among patients with AQP4-positive NMOSD and was well tolerated [2]. The presented long-term results centred on the 33 patients who received eculizumab as monotherapy during PREVENT and/or its open-label extension (OLE), for a total of 85.3 patient-years (PY). In PREVENT, 1 of these 33 patients had experienced an adjudicated relapse versus 7 of 13 with placebo alone.
After 192 weeks, 96.2% and 93.8% of patients who received eculizumab monotherapy or eculizumab with concomitant immunosuppressive therapy (IST), respectively, were relapse-free. No patients receiving eculizumab monotherapy were hospitalised for a relapse or started IST.
Eculizumab has generally been well tolerated in the short- and longer term in patients who received the drug in the PREVENT study and/or its ongoing OLE. The number of adverse events (AEs) after 192 weeks that were related to treatment with eculizumab monotherapy (PREVENT + OLE) were similar to placebo alone in PREVENT: 181.0 and 186.0 events per 100 PY, respectively. The infection rate was also similar: 174.1 versus 186.0 events per 100 PY. There were no meningococcal infections or deaths. Actually, there were less treatment-related serious AEs with eculizumab monotherapy than with placebo (5.7 vs 23.3 per 100 PY).
- Pittock S, et al. Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder. MSVirtual 2020, Abstract FC01.01.
- Pittock SJ, et al. N Engl J Med. 2019;381(7):614-25.
Posted on
Previous Article
« Satralizumab lowers risk of severe relapse in NMOSD patients Next Article
NG-specific biomarkers differentiate NMOSD from MS »
« Satralizumab lowers risk of severe relapse in NMOSD patients Next Article
NG-specific biomarkers differentiate NMOSD from MS »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
September 10, 2020
Two trials comparing relapsing MS treatments
November 25, 2020
Predictive value of CSF Aβ and tau proteins in MS
November 25, 2020
Lesion-specific perfusion levels affect myelin loss and repair
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy